Dementia Screening Moves from Clinic to Cassette

One Step Dementia Risk Test Kit

Population-level screening for dementia has long been constrained by cost and infrastructure. PET scans and lumbar punctures are precise but impractical for routine use. This test, manufactured in China with NMPA and CE approval, offers an alternative built for scale.

It detects amyloid-beta concentration in urine using colloidal gold lateral immunochromatography. The workflow is straightforward: four drops of fresh midstream urine produce a result in ten minutes. No lab, no blood draw, no specialist required.

The test is intended as an auxiliary screening device for dementia risk, including Alzheimer’s disease. Performance data shows a sensitivity of 79.14% and specificity of 91.03%, with a Kappa value of 0.704 against reference methods. It flags risk but does not diagnose.

Target users include individuals over 45, those with family history, chronic conditions, or cognitive complaints. The test slots into routine physical exams, community health checks, and occupational wellness programs where earlier detection may alter care pathways.

Its core advantage lies in supply chain simplicity. Urine-based testing eliminates cold-chain logistics for serum handling, reduces consumable costs, and allows decentralized storage. This makes it viable for township hospitals and remote health stations where centralized lab capacity is absent.

The test uses self-developed Aβ monoclonal antibodies paired with a polymer sandwich method. This in-house antibody production reduces reliance on imported reagents and insulates the supply chain from foreign sourcing disruptions—a structural advantage for China’s domestic diagnostic ecosystem.

The real shift here is not the biomarker. It is that cognitive risk assessment has been packaged into a format that fits existing procurement frameworks for rapid diagnostic tests. That standardization is what makes population-wide screening logistically plausible.

Why it matters:
For hospital procurement managers and diagnostic distributors, this product reduces the operational cost of dementia screening to that of a urine strip test. For public health planners, it provides a tool that can be deployed without specialized training or expensive equipment. The kit’s domestic antibody supply chain also offers price stability and procurement security in a market increasingly prioritizing local sourcing.

View Product →